RNA-Based Therapeutics and Vaccines Market Forecast 2024-2034
Market Overview The RNA-Based Therapeutics and Vaccines Market is entering a transformative decade. Valued at approximately USD 4.8 billion in 2024, the market is projected to reach nearly USD 25.3 billion by 2034, registering a compound annual growth rate (CAGR) of around 18.1%. This remarkable expansion reflects a paradigm shift in how diseases are treated and prevented, moving from conventional small molecules and protein-based biologics toward programmable RNA platforms. RNA-based technologies utilize ribonucleic acid to direct cellular machinery for therapeutic benefit. The market includes messenger RNA (mRNA) vaccines, RNA interference (RNAi) therapeutics, and antisense oligonucleotides (ASOs). These approaches allow precise modulation of gene expression and protein synthesis, enabling targeted intervention across infectious diseases, oncology, rare genetic disorders, and autoimmune conditions. The success of mRNA vaccines during the COVID-19 pandemic demonstrated not only...